Edwards Lifesciences Corporation
EW
$67.95
-$0.56-0.82%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.32% | 0.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.32% | 0.15% | |||
| Cost of Revenue | 11.14% | -1.20% | |||
| Gross Profit | 0.19% | 0.48% | |||
| SG&A Expenses | 16.59% | -4.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -201.34% | -- | |||
| Total Operating Expenses | 7.48% | -2.02% | |||
| Operating Income | -10.25% | 5.85% | |||
| Income Before Tax | -3.15% | 5.47% | |||
| Income Tax Expenses | 10.81% | 106.60% | |||
| Earnings from Continuing Operations | -4.72% | -0.03% | |||
| Earnings from Discontinued Operations | -98.55% | 96,589.29% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -7.14% | 7.69% | |||
| Net Income | -87.44% | 738.33% | |||
| EBIT | -10.25% | 5.85% | |||
| EBITDA | -7.53% | 4.05% | |||
| EPS Basic | -87.29% | 745.17% | |||
| Normalized Basic EPS | -15.06% | 14.90% | |||
| EPS Diluted | -87.29% | 749.92% | |||
| Normalized Diluted EPS | -15.04% | 15.15% | |||
| Average Basic Shares Outstanding | -1.24% | -0.81% | |||
| Average Diluted Shares Outstanding | -1.27% | -1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
